NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Barchart · 2d ago

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.